Blood最新文献

{"title":"PROTACtion against BCL-xL in post-MPN AML.","authors":"Nicole S Arellano,Shannon E Elf","doi":"10.1182/blood.2025029273","DOIUrl":"https://doi.org/10.1182/blood.2025029273","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"30 1","pages":"266-267"},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masthead Subscription","authors":"","doi":"10.1016/s0006-4971(25)01528-9","DOIUrl":"https://doi.org/10.1016/s0006-4971(25)01528-9","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"76 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"m6A meets T-ALL: HNRNPC and FTO as new therapeutic targets.","authors":"Xueqin Xie,Michael G Kharas","doi":"10.1182/blood.2025029382","DOIUrl":"https://doi.org/10.1182/blood.2025029382","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"24 1","pages":"261-262"},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.","authors":"De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye","doi":"10.1182/blood.2024026139","DOIUrl":"10.1182/blood.2024026139","url":null,"abstract":"<p><strong>Abstract: </strong>Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome, and the overall survival (OS) of adult patients is poor. Ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor, has shown promise in treating HLH and exerts synergistic effects when combined with dexamethasone. Our pilot study preliminarily demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult patients with HLH. In this prospective phase 2 clinical trial, we propose the Ru-D regimen as a first-line treatment for adults newly diagnosed as having HLH with unknown triggers. A total of 28 Chinese patients were enrolled, and the median follow-up time was 25.1 months (range, 0.87-34.0). The 2-month OS rate (the primary end point) was 85.7%, which exceeded our expected 2-month OS rate of 75%. The 6-month and 2-year OS rates were 67.9% (19/28) and 53.6% (15/28), respectively. The median OS of patients with lymphoma-associated HLH (LAHS) was 5.8 months, and most of these patients had natural killer/T-cell lymphoma. In contrast, the 2-year OS rate of patients without LAHS was 75%. The overall response rate was 85.7% (24/28); of 28 patients, 5 (17.9%) achieved a complete response during the Ru-D regimen. Overall, the Ru-D regimen was well tolerated in patients with HLH. This study demonstrates the efficacy and safety of the Ru-D regimen in adults newly diagnosed as having HLH with unknown triggers and warrants a phase 3 randomized controlled study. This trial was registered at www.chictr.org.cn as #ChiCTR2100049996).</p>","PeriodicalId":9102,"journal":{"name":"Blood","volume":" ","pages":"318-327"},"PeriodicalIF":21.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756-768.","authors":"","doi":"10.1182/blood.2025029967","DOIUrl":"https://doi.org/10.1182/blood.2025029967","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"12 1","pages":"397"},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative low VWF.","authors":"","doi":"10.1182/blood.2025030186","DOIUrl":"https://doi.org/10.1182/blood.2025030186","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"146 3","pages":"398"},"PeriodicalIF":21.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Richter transformation recommendations.","authors":"Birgitta Sander","doi":"10.1182/blood.2025029450","DOIUrl":"https://doi.org/10.1182/blood.2025029450","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"146 3","pages":"262-263"},"PeriodicalIF":21.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic drug remedies for SCD root cause pathophysiology.","authors":"Yogen Saunthararajah,Donald Lavelle","doi":"10.1182/blood.2025029447","DOIUrl":"https://doi.org/10.1182/blood.2025029447","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"678 1","pages":"268-270"},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 1 von Willebrand disease: does it need a sibling?","authors":"Ravi Sarode","doi":"10.1182/blood.2025029448","DOIUrl":"https://doi.org/10.1182/blood.2025029448","url":null,"abstract":"","PeriodicalId":9102,"journal":{"name":"Blood","volume":"37 1","pages":"270-271"},"PeriodicalIF":20.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFκB signaling.","authors":"Paran Goel,Sajesan Aryal,Alana M Franceski,Valeriya Kuznetsova,Amanda Fernandes De Oliveira Costa,Francesca Luca,Ashley N Connelly,Daniel W Phillips,Caroline C Ennis,Brittany M Curtiss,Sourajeet Karfa,Brittany L Crown,Christina R Larson,Estelle Carminita,Virginia Camacho,Doug Welsch,Changde Cheng,Asumi Yokota,Isidoro Cobo,Hideyo Hirai,Rui Lu,Ravi Bhatia,Pran K Datta,Paul Brent Ferrell,Robert S Welner","doi":"10.1182/blood.2024028199","DOIUrl":"https://doi.org/10.1182/blood.2024028199","url":null,"abstract":"Acute myeloid leukemia (AML), an aggressive hematological malignancy, is driven by oncogenic mutations in stem and progenitor cells that give rise to AML blasts. While these mutations are well-characterized, their impact on healthy hematopoiesis-those blood cells exposed to AML but not mutated-has not been well-characterized. As the marrow is the major site for granulopoiesis, neutrophils are heavily influenced by AML pathobiology. Indeed, most AML patients report neutropenia, rendering them susceptible to infections. However, since AML studies use peripheral blood mononuclear cells devoid of neutrophils, the characterization of neutrophil dysfunction remains poorly understood. To investigate AML-exposed neutrophils, a pre-clinical AML mouse model was used where primary leukemic cells were transplanted into non-irradiated neutrophil reporter (Ly6G-tdTomato; Catchup) hosts. Neutrophils could not completely mature, suggesting impaired granulopoiesis. Single-cell transcriptomics of AML-exposed neutrophils revealed higher inflammation signatures and expression of CD14, an inflammatory marker. To address the factors contributing to this biology, an ex vivo cytokine screen was performed on marrow neutrophils and identified that NFκB signaling drove CD14 expression. AML-exposed neutrophils displayed widespread chromatin remodeling, and de novo motif discovery predicted increased binding sites for CCAAT-enhancer-binding proteins (C/EBPs) and Interferon regulatory factors (IRFs). Moreover, AML-exposed neutrophils inhibited T-cell proliferation, highlighting their immune-suppressive capability. Finally, similar biology of immature, inflammatory neutrophils was found in AML patients, again indicating dysregulated granulopoiesis. Collectively, these data show that AML-associated inflammation alters neutrophil granulopoiesis, impairs neutrophil function, and drives immunosuppression, thus contributing to patient susceptibility to infection.","PeriodicalId":9102,"journal":{"name":"Blood","volume":"29 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}